Shares of NeoGenomics (NEO) fell over 10% after the oncology diagnostics company reported fourth-quarter results that beat expectations but issued a full-year 2026 forecast falling short of analyst predictions. Despite an 11% revenue growth in Q4 2025, the increased net loss for the full year 2025 and lower-than-anticipated 2026 guidance led to a negative market reaction. The company’s stock has been highly volatile, with significant drops in the past year, and is currently trading 22.6% below its 52-week high.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Why NeoGenomics (NEO) Shares Are Falling Today
Shares of NeoGenomics (NEO) fell over 10% after the oncology diagnostics company reported fourth-quarter results that beat expectations but issued a full-year 2026 forecast falling short of analyst predictions. Despite an 11% revenue growth in Q4 2025, the increased net loss for the full year 2025 and lower-than-anticipated 2026 guidance led to a negative market reaction. The company’s stock has been highly volatile, with significant drops in the past year, and is currently trading 22.6% below its 52-week high.